| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 219 | 2024 | 1596 | 26.010 |
Why?
|
| Lymphocytosis | 24 | 2023 | 119 | 8.500 |
Why?
|
| Receptors, Antigen, B-Cell | 37 | 2023 | 548 | 4.540 |
Why?
|
| B-Lymphocytes | 59 | 2023 | 4665 | 4.450 |
Why?
|
| Pyrazoles | 24 | 2022 | 1970 | 2.850 |
Why?
|
| Pyrimidines | 25 | 2022 | 2945 | 2.540 |
Why?
|
| Genes, Immunoglobulin | 13 | 2024 | 291 | 2.210 |
Why?
|
| Adenine | 31 | 2022 | 935 | 2.000 |
Why?
|
| Immunoglobulin Heavy Chains | 30 | 2024 | 659 | 1.970 |
Why?
|
| Piperidines | 37 | 2023 | 1601 | 1.940 |
Why?
|
| Immunoglobulin Variable Region | 24 | 2024 | 421 | 1.590 |
Why?
|
| Pyrazines | 12 | 2023 | 1230 | 1.470 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 10 | 2022 | 180 | 1.440 |
Why?
|
| Benzamides | 11 | 2022 | 1383 | 1.350 |
Why?
|
| Toll-Like Receptors | 11 | 2023 | 593 | 1.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 33 | 2023 | 11524 | 1.270 |
Why?
|
| Complementarity Determining Regions | 10 | 2020 | 149 | 1.220 |
Why?
|
| Neoplasm, Residual | 9 | 2022 | 973 | 1.170 |
Why?
|
| Lymphoma, Follicular | 7 | 2022 | 435 | 1.170 |
Why?
|
| Hematologic Neoplasms | 8 | 2023 | 1832 | 1.130 |
Why?
|
| Antineoplastic Agents | 32 | 2023 | 13691 | 1.110 |
Why?
|
| Quinazolinones | 11 | 2022 | 221 | 1.090 |
Why?
|
| Lymphoma, Mantle-Cell | 8 | 2022 | 233 | 1.080 |
Why?
|
| Lymphocyte Count | 14 | 2021 | 793 | 1.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 17 | 2021 | 651 | 1.040 |
Why?
|
| Lymphoma, B-Cell | 11 | 2022 | 931 | 1.030 |
Why?
|
| Precancerous Conditions | 5 | 2023 | 975 | 1.020 |
Why?
|
| Purines | 13 | 2022 | 590 | 1.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2016 | 693 | 1.000 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 10 | 2015 | 92 | 0.970 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2023 | 2944 | 0.940 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 16 | 2021 | 97 | 0.940 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2023 | 5532 | 0.920 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2020 | 437 | 0.910 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 177 | 0.910 |
Why?
|
| Antigens, Neoplasm | 6 | 2020 | 1988 | 0.890 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 4 | 2021 | 57 | 0.850 |
Why?
|
| Splenic Neoplasms | 6 | 2022 | 100 | 0.840 |
Why?
|
| Immunogenetics | 7 | 2018 | 67 | 0.840 |
Why?
|
| Lymphoma | 5 | 2022 | 1875 | 0.840 |
Why?
|
| Chlorambucil | 6 | 2022 | 43 | 0.820 |
Why?
|
| Chromosome Deletion | 6 | 2020 | 1396 | 0.810 |
Why?
|
| Leukemia, B-Cell | 4 | 2016 | 86 | 0.800 |
Why?
|
| Humans | 263 | 2024 | 743811 | 0.770 |
Why?
|
| Immunophenotyping | 18 | 2022 | 1880 | 0.770 |
Why?
|
| Immunoglobulins | 9 | 2022 | 881 | 0.740 |
Why?
|
| Vidarabine | 7 | 2020 | 345 | 0.730 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2020 | 880 | 0.680 |
Why?
|
| Prognosis | 38 | 2022 | 29052 | 0.620 |
Why?
|
| Mutation | 36 | 2024 | 29777 | 0.620 |
Why?
|
| Sequence Analysis, Protein | 1 | 2018 | 258 | 0.600 |
Why?
|
| Chemokines, CC | 4 | 2003 | 290 | 0.580 |
Why?
|
| Pyridinium Compounds | 1 | 2017 | 83 | 0.580 |
Why?
|
| Chromosome Aberrations | 8 | 2022 | 1811 | 0.570 |
Why?
|
| Hedgehogs | 1 | 2015 | 4 | 0.540 |
Why?
|
| Clonal Anergy | 3 | 2016 | 169 | 0.540 |
Why?
|
| Hematology | 2 | 2020 | 221 | 0.480 |
Why?
|
| Apoptosis | 16 | 2024 | 9718 | 0.480 |
Why?
|
| Aged | 79 | 2023 | 163178 | 0.470 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 286 | 0.460 |
Why?
|
| Aged, 80 and over | 45 | 2023 | 57744 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2022 | 9239 | 0.460 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2023 | 5170 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 7 | 2018 | 9272 | 0.440 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 1023 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 8430 | 0.440 |
Why?
|
| Multiple Myeloma | 5 | 2023 | 5185 | 0.430 |
Why?
|
| High-Throughput Nucleotide Sequencing | 11 | 2022 | 3591 | 0.430 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 640 | 0.430 |
Why?
|
| Tumor Microenvironment | 16 | 2023 | 3583 | 0.420 |
Why?
|
| Lectins | 1 | 2014 | 513 | 0.400 |
Why?
|
| Clone Cells | 9 | 2013 | 1692 | 0.400 |
Why?
|
| Sulfonamides | 7 | 2023 | 1938 | 0.400 |
Why?
|
| Flow Cytometry | 12 | 2019 | 5973 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2016 | 1434 | 0.400 |
Why?
|
| T-Lymphocytes | 14 | 2023 | 10179 | 0.390 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2022 | 42 | 0.390 |
Why?
|
| Immunotherapy | 6 | 2019 | 4437 | 0.380 |
Why?
|
| Leukemia | 1 | 2018 | 1509 | 0.360 |
Why?
|
| Blood Proteins | 6 | 2016 | 1125 | 0.360 |
Why?
|
| Male | 93 | 2023 | 349776 | 0.360 |
Why?
|
| Bone Marrow | 10 | 2022 | 2951 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 8 | 2019 | 2727 | 0.340 |
Why?
|
| Female | 92 | 2022 | 380020 | 0.340 |
Why?
|
| Stromal Cells | 7 | 2022 | 1356 | 0.330 |
Why?
|
| Cyclophosphamide | 5 | 2020 | 2241 | 0.320 |
Why?
|
| Leukocytosis | 1 | 2010 | 247 | 0.320 |
Why?
|
| Signal Transduction | 25 | 2023 | 23398 | 0.320 |
Why?
|
| Middle Aged | 68 | 2023 | 213241 | 0.320 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 6895 | 0.320 |
Why?
|
| Recurrence | 10 | 2023 | 8337 | 0.310 |
Why?
|
| Cell Lineage | 2 | 2014 | 2506 | 0.310 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 1157 | 0.310 |
Why?
|
| Genomics | 5 | 2022 | 5714 | 0.290 |
Why?
|
| Survival Analysis | 12 | 2021 | 10251 | 0.290 |
Why?
|
| Mice, Transgenic | 14 | 2024 | 9731 | 0.290 |
Why?
|
| Disease Progression | 18 | 2020 | 13273 | 0.280 |
Why?
|
| Immunoglobulin M | 5 | 2022 | 1537 | 0.270 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 11036 | 0.270 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 6 | 2019 | 111 | 0.270 |
Why?
|
| Burkitt Lymphoma | 4 | 2001 | 326 | 0.270 |
Why?
|
| Animals | 45 | 2024 | 168660 | 0.260 |
Why?
|
| Receptors, Chemokine | 3 | 2003 | 670 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3134 | 0.260 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2020 | 87 | 0.260 |
Why?
|
| Neoplasm Proteins | 6 | 2015 | 3706 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3241 | 0.260 |
Why?
|
| DNA Mutational Analysis | 9 | 2019 | 4183 | 0.260 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 2016 | 675 | 0.260 |
Why?
|
| MAP Kinase Signaling System | 4 | 2022 | 1524 | 0.250 |
Why?
|
| Immunoglobulin Light Chains | 5 | 2017 | 277 | 0.250 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2017 | 211 | 0.250 |
Why?
|
| Mice | 30 | 2024 | 81154 | 0.240 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 627 | 0.240 |
Why?
|
| ADP-ribosyl Cyclase | 2 | 2005 | 38 | 0.240 |
Why?
|
| Congresses as Topic | 1 | 2009 | 763 | 0.240 |
Why?
|
| Lymphocyte Activation | 13 | 2021 | 5524 | 0.240 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2020 | 1381 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2021 | 4386 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 627 | 0.230 |
Why?
|
| Mutagenesis, Insertional | 1 | 2006 | 654 | 0.230 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 18027 | 0.230 |
Why?
|
| Survival Rate | 11 | 2021 | 12786 | 0.230 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2017 | 262 | 0.230 |
Why?
|
| Autoantigens | 3 | 2017 | 892 | 0.220 |
Why?
|
| Gene Deletion | 3 | 2015 | 2749 | 0.220 |
Why?
|
| MicroRNAs | 5 | 2016 | 3750 | 0.220 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 118 | 0.220 |
Why?
|
| Sequoia | 1 | 2022 | 6 | 0.220 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1271 | 0.220 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2022 | 7 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 11 | 2021 | 6311 | 0.210 |
Why?
|
| Treatment Outcome | 22 | 2022 | 63042 | 0.210 |
Why?
|
| Genes, bcl-2 | 2 | 2003 | 122 | 0.210 |
Why?
|
| Myeloid Differentiation Factor 88 | 5 | 2022 | 571 | 0.210 |
Why?
|
| Chemokines | 3 | 2021 | 968 | 0.210 |
Why?
|
| Dromaiidae | 1 | 2021 | 7 | 0.210 |
Why?
|
| CD40 Ligand | 6 | 2021 | 526 | 0.210 |
Why?
|
| Chemokines, CXC | 2 | 2003 | 422 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2020 | 1794 | 0.200 |
Why?
|
| Cell Movement | 9 | 2016 | 5216 | 0.200 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 199 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 17439 | 0.200 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 39001 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 1781 | 0.200 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 1029 | 0.200 |
Why?
|
| Hemorrhage | 7 | 2023 | 3458 | 0.190 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2020 | 29 | 0.190 |
Why?
|
| Italy | 4 | 2018 | 829 | 0.190 |
Why?
|
| Amino Acid Sequence | 13 | 2018 | 13809 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 7908 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2021 | 4552 | 0.190 |
Why?
|
| NF-kappa B | 4 | 2024 | 2500 | 0.190 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2020 | 21 | 0.190 |
Why?
|
| Cell Communication | 4 | 2016 | 1621 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2022 | 13028 | 0.190 |
Why?
|
| Isoquinolines | 2 | 2020 | 364 | 0.180 |
Why?
|
| Tosyl Compounds | 1 | 2020 | 113 | 0.180 |
Why?
|
| Immunological Synapses | 1 | 2020 | 54 | 0.180 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 5033 | 0.180 |
Why?
|
| Vaccines, Subunit | 1 | 2020 | 168 | 0.180 |
Why?
|
| Adult | 41 | 2023 | 213889 | 0.180 |
Why?
|
| DNA Methylation | 4 | 2019 | 4286 | 0.180 |
Why?
|
| Quality of Life | 2 | 2022 | 12788 | 0.180 |
Why?
|
| Extracellular Space | 1 | 2002 | 595 | 0.180 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2015 | 67 | 0.180 |
Why?
|
| Tretinoin | 2 | 2018 | 517 | 0.180 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 707 | 0.180 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 78 | 0.180 |
Why?
|
| Phenotype | 11 | 2022 | 16361 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2019 | 2850 | 0.180 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 1859 | 0.170 |
Why?
|
| Immunoglobulin D | 2 | 2016 | 56 | 0.170 |
Why?
|
| Diagnosis, Differential | 7 | 2018 | 12954 | 0.170 |
Why?
|
| Spleen | 5 | 2022 | 2359 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 3547 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1837 | 0.170 |
Why?
|
| Aspergillus fumigatus | 1 | 2020 | 150 | 0.170 |
Why?
|
| Autoimmunity | 1 | 2007 | 1349 | 0.170 |
Why?
|
| Ecosystem | 1 | 2023 | 473 | 0.170 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 74 | 0.160 |
Why?
|
| Taiwan | 2 | 2017 | 497 | 0.160 |
Why?
|
| Salvage Therapy | 4 | 2020 | 1275 | 0.160 |
Why?
|
| Hereditary Angioedema Types I and II | 1 | 2018 | 10 | 0.160 |
Why?
|
| Antigens, CD | 6 | 2012 | 4026 | 0.160 |
Why?
|
| Aspergillosis | 1 | 2020 | 235 | 0.160 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2018 | 158 | 0.160 |
Why?
|
| Cell Survival | 10 | 2021 | 5881 | 0.160 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2019 | 291 | 0.160 |
Why?
|
| DNA-Binding Proteins | 6 | 2015 | 9648 | 0.160 |
Why?
|
| Cytogenetics | 1 | 2019 | 203 | 0.160 |
Why?
|
| Epigenomics | 2 | 2021 | 903 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1063 | 0.160 |
Why?
|
| Retrospective Studies | 13 | 2023 | 77410 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2016 | 294 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2015 | 805 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 1836 | 0.160 |
Why?
|
| Cell Line, Tumor | 13 | 2022 | 16674 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2005 | 1821 | 0.160 |
Why?
|
| Disease Management | 4 | 2018 | 2459 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 392 | 0.150 |
Why?
|
| Bone Marrow Cells | 4 | 2012 | 2509 | 0.150 |
Why?
|
| Antigens | 3 | 2023 | 1466 | 0.150 |
Why?
|
| Translocation, Genetic | 4 | 2016 | 1420 | 0.150 |
Why?
|
| Anilides | 1 | 2020 | 409 | 0.150 |
Why?
|
| Neoplasm Transplantation | 4 | 2020 | 2085 | 0.150 |
Why?
|
| Gene Rearrangement | 5 | 2021 | 1179 | 0.150 |
Why?
|
| Indolizines | 1 | 2017 | 36 | 0.150 |
Why?
|
| Macrophages | 3 | 2020 | 5651 | 0.150 |
Why?
|
| Chemokine CCL22 | 3 | 2002 | 25 | 0.150 |
Why?
|
| Cyclic N-Oxides | 1 | 2017 | 78 | 0.150 |
Why?
|
| Cells, Cultured | 11 | 2017 | 19232 | 0.150 |
Why?
|
| Coculture Techniques | 6 | 2021 | 1342 | 0.150 |
Why?
|
| Cell Culture Techniques | 2 | 2022 | 1677 | 0.140 |
Why?
|
| Preleukemia | 3 | 2010 | 35 | 0.140 |
Why?
|
| Camptothecin | 1 | 2020 | 576 | 0.140 |
Why?
|
| Aging | 2 | 2007 | 8655 | 0.140 |
Why?
|
| I-kappa B Proteins | 1 | 2017 | 225 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 390 | 0.140 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 93 | 0.140 |
Why?
|
| Chromogranin A | 1 | 2016 | 54 | 0.140 |
Why?
|
| Calreticulin | 1 | 2017 | 98 | 0.140 |
Why?
|
| Consensus | 3 | 2022 | 2954 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 4477 | 0.140 |
Why?
|
| Cysteine | 1 | 2021 | 871 | 0.140 |
Why?
|
| Receptors, Notch | 1 | 2021 | 739 | 0.140 |
Why?
|
| Cytidine Deaminase | 2 | 2015 | 252 | 0.140 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 844 | 0.130 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 110 | 0.130 |
Why?
|
| Base Sequence | 4 | 2018 | 12798 | 0.130 |
Why?
|
| Binding, Competitive | 1 | 2017 | 1157 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.130 |
Why?
|
| Nitriles | 1 | 2020 | 953 | 0.130 |
Why?
|
| Azacitidine | 1 | 2017 | 347 | 0.130 |
Why?
|
| Hypertension | 4 | 2023 | 8480 | 0.130 |
Why?
|
| Gene Expression Profiling | 9 | 2019 | 9440 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2014 | 197 | 0.130 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 45 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2017 | 2916 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2017 | 496 | 0.120 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2014 | 278 | 0.120 |
Why?
|
| Gene Frequency | 6 | 2021 | 3585 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 6380 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 1181 | 0.120 |
Why?
|
| Receptors, Antigen | 1 | 2014 | 53 | 0.120 |
Why?
|
| DNA, Antisense | 1 | 2013 | 46 | 0.120 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 252 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 354 | 0.120 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 316 | 0.120 |
Why?
|
| Thionucleotides | 1 | 2013 | 107 | 0.120 |
Why?
|
| Blotting, Western | 3 | 2017 | 5179 | 0.120 |
Why?
|
| Sweden | 1 | 2016 | 1341 | 0.120 |
Why?
|
| Monocytes | 1 | 2003 | 2593 | 0.110 |
Why?
|
| Diarrhea | 5 | 2019 | 1348 | 0.110 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 360 | 0.110 |
Why?
|
| Mice, Knockout | 6 | 2016 | 14563 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2020 | 10477 | 0.110 |
Why?
|
| Age Factors | 3 | 2020 | 18355 | 0.110 |
Why?
|
| Remission Induction | 3 | 2015 | 2384 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15526 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 2009 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2014 | 171 | 0.110 |
Why?
|
| Membrane Glycoproteins | 6 | 2012 | 3769 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 2012 | 6170 | 0.110 |
Why?
|
| Cladribine | 1 | 2012 | 34 | 0.110 |
Why?
|
| Molecular Sequence Data | 8 | 2014 | 18107 | 0.110 |
Why?
|
| Gene Expression | 7 | 2021 | 7793 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 2453 | 0.110 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 3645 | 0.110 |
Why?
|
| Chemokine CCL17 | 2 | 2002 | 23 | 0.110 |
Why?
|
| Alleles | 4 | 2016 | 6934 | 0.100 |
Why?
|
| Thalidomide | 1 | 2017 | 890 | 0.100 |
Why?
|
| Biomimetics | 1 | 2013 | 172 | 0.100 |
Why?
|
| Models, Biological | 6 | 2015 | 9582 | 0.100 |
Why?
|
| Cohort Studies | 11 | 2021 | 40545 | 0.100 |
Why?
|
| Iron | 1 | 2020 | 1774 | 0.100 |
Why?
|
| Cytoskeleton | 3 | 2014 | 1185 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2014 | 381 | 0.100 |
Why?
|
| Flavonoids | 1 | 2015 | 443 | 0.100 |
Why?
|
| Gene Targeting | 1 | 2015 | 879 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 7270 | 0.100 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 1376 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1377 | 0.100 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 5854 | 0.100 |
Why?
|
| Blood Donors | 1 | 2013 | 355 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2014 | 755 | 0.100 |
Why?
|
| Receptors, IgE | 2 | 2011 | 389 | 0.100 |
Why?
|
| Protein Binding | 3 | 2017 | 9377 | 0.100 |
Why?
|
| Risk Factors | 7 | 2022 | 72252 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2005 | 295 | 0.100 |
Why?
|
| Chemokine CXCL13 | 2 | 2018 | 54 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2012 | 2615 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2019 | 3000 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3175 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 524 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 784 | 0.090 |
Why?
|
| Neutropenia | 3 | 2023 | 895 | 0.090 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 2703 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2010 | 284 | 0.090 |
Why?
|
| Cell Differentiation | 5 | 2012 | 11478 | 0.090 |
Why?
|
| Mortality | 1 | 2021 | 2862 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8385 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 551 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 462 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1670 | 0.090 |
Why?
|
| Indoles | 2 | 2019 | 1841 | 0.090 |
Why?
|
| Vaccination | 1 | 2022 | 3275 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5445 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 4803 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 323 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4931 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 3389 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 2914 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2014 | 8436 | 0.080 |
Why?
|
| Thrombosis | 1 | 2022 | 2968 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6539 | 0.080 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 457 | 0.080 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 173 | 0.080 |
Why?
|
| Chlamydophila psittaci | 1 | 2007 | 2 | 0.080 |
Why?
|
| Canaries | 1 | 2007 | 6 | 0.080 |
Why?
|
| Europe | 3 | 2020 | 3336 | 0.080 |
Why?
|
| Bird Diseases | 1 | 2007 | 19 | 0.080 |
Why?
|
| Chlamydophila Infections | 1 | 2007 | 23 | 0.080 |
Why?
|
| Cell Death | 1 | 2013 | 1705 | 0.080 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2007 | 71 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 454 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2020 | 3740 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 2942 | 0.080 |
Why?
|
| Prevalence | 4 | 2019 | 15211 | 0.080 |
Why?
|
| Software | 2 | 2021 | 4440 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 21824 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2649 | 0.070 |
Why?
|
| Lymphotoxin-alpha | 2 | 2012 | 98 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2007 | 112 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 602 | 0.070 |
Why?
|
| Epitopes | 2 | 2011 | 2570 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 5867 | 0.070 |
Why?
|
| Pyrroles | 1 | 2013 | 1147 | 0.070 |
Why?
|
| Cell Adhesion | 4 | 2021 | 3144 | 0.070 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2006 | 46 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2014 | 2440 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2016 | 245 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2019 | 4749 | 0.070 |
Why?
|
| Multigene Family | 2 | 2022 | 1101 | 0.070 |
Why?
|
| Palliative Care | 1 | 2021 | 3490 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2016 | 299 | 0.070 |
Why?
|
| Cell Line | 5 | 2021 | 15993 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2015 | 2566 | 0.070 |
Why?
|
| Jurkat Cells | 1 | 2008 | 743 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2016 | 2378 | 0.070 |
Why?
|
| Fatigue | 3 | 2019 | 1530 | 0.070 |
Why?
|
| Tumor Escape | 2 | 2021 | 350 | 0.070 |
Why?
|
| NFATC Transcription Factors | 1 | 2008 | 381 | 0.070 |
Why?
|
| Immunity, Innate | 2 | 2020 | 2961 | 0.070 |
Why?
|
| Comorbidity | 1 | 2020 | 10380 | 0.070 |
Why?
|
| Lacrimal Apparatus | 1 | 2007 | 225 | 0.070 |
Why?
|
| Eye Neoplasms | 1 | 2007 | 312 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2006 | 246 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2017 | 1898 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 15518 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 4033 | 0.060 |
Why?
|
| Mediterranean Region | 1 | 2004 | 47 | 0.060 |
Why?
|
| Retreatment | 2 | 2018 | 609 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2017 | 708 | 0.060 |
Why?
|
| Age Distribution | 1 | 2010 | 2899 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 9944 | 0.060 |
Why?
|
| Genes, bcl-1 | 1 | 2003 | 11 | 0.060 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2002 | 53 | 0.060 |
Why?
|
| Research Personnel | 1 | 2009 | 573 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2014 | 3492 | 0.060 |
Why?
|
| Pedigree | 2 | 2008 | 4643 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 890 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2012 | 2258 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5096 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2022 | 4221 | 0.060 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 123 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2018 | 1460 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2006 | 2540 | 0.060 |
Why?
|
| Chemokine CCL20 | 1 | 2003 | 65 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12020 | 0.060 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2023 | 86 | 0.060 |
Why?
|
| Receptors, CCR6 | 1 | 2003 | 81 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2004 | 343 | 0.050 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 326 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2019 | 3917 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2002 | 92 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 315 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2010 | 1378 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2022 | 87 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 2 | 2002 | 1376 | 0.050 |
Why?
|
| Receptors, CCR4 | 1 | 2002 | 81 | 0.050 |
Why?
|
| Semaphorins | 1 | 2002 | 101 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2003 | 236 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2016 | 3476 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2004 | 527 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2002 | 262 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4561 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2019 | 12209 | 0.050 |
Why?
|
| Time Factors | 6 | 2020 | 40038 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 379 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 1423 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 577 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2020 | 4422 | 0.050 |
Why?
|
| Chemotactic Factors | 1 | 2001 | 199 | 0.050 |
Why?
|
| Nod2 Signaling Adaptor Protein | 2 | 2012 | 87 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2012 | 3024 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2003 | 620 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 339 | 0.050 |
Why?
|
| Virus Activation | 1 | 2022 | 319 | 0.050 |
Why?
|
| Glycosylation | 1 | 2023 | 1129 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 637 | 0.050 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 30 | 0.050 |
Why?
|
| Incidence | 3 | 2018 | 20948 | 0.050 |
Why?
|
| Antigens, CD19 | 3 | 2011 | 380 | 0.040 |
Why?
|
| Young Adult | 5 | 2017 | 56392 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2021 | 278 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2021 | 4204 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2504 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 1998 | 18 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2014 | 7729 | 0.040 |
Why?
|
| Aldehyde Oxidase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2018 | 19 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2021 | 5445 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2002 | 1147 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 694 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2023 | 783 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2022 | 513 | 0.040 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 1366 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 115 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2022 | 775 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 2004 | 5021 | 0.040 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2018 | 97 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3089 | 0.040 |
Why?
|
| Common Variable Immunodeficiency | 1 | 1998 | 93 | 0.040 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2017 | 95 | 0.040 |
Why?
|
| Aptamers, Nucleotide | 1 | 2019 | 166 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 1998 | 107 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2015 | 1793 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2019 | 1707 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 290 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2019 | 376 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11059 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2004 | 1347 | 0.040 |
Why?
|
| Anticoagulants | 3 | 2022 | 4599 | 0.040 |
Why?
|
| Histones | 2 | 2019 | 2598 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 2217 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 1918 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 1320 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 84 | 0.040 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2016 | 36 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 2016 | 129 | 0.040 |
Why?
|
| World Health Organization | 1 | 2022 | 1317 | 0.040 |
Why?
|
| Chick Embryo | 1 | 1998 | 983 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1520 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2018 | 383 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2017 | 220 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 541 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21733 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4326 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 1998 | 411 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2021 | 2011 | 0.030 |
Why?
|
| Clodronic Acid | 1 | 2016 | 58 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 528 | 0.030 |
Why?
|
| Automation | 1 | 2018 | 584 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 193 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2017 | 411 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.030 |
Why?
|
| Hydrogels | 1 | 2021 | 727 | 0.030 |
Why?
|
| Adolescent | 5 | 2014 | 85729 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2001 | 1283 | 0.030 |
Why?
|
| Dimerization | 1 | 2017 | 894 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2004 | 2720 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
| Mice, Inbred NZB | 1 | 2014 | 56 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2018 | 297 | 0.030 |
Why?
|
| Actins | 2 | 2014 | 2121 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2020 | 1539 | 0.030 |
Why?
|
| Receptor, Notch2 | 1 | 2015 | 89 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2012 | 2712 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 1676 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 711 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 11360 | 0.030 |
Why?
|
| Point Mutation | 1 | 2020 | 1623 | 0.030 |
Why?
|
| Safety | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 2029 | 0.030 |
Why?
|
| DNA Primers | 1 | 1999 | 2891 | 0.030 |
Why?
|
| DNA Replication | 1 | 2021 | 1399 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2017 | 436 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2021 | 956 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4251 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2014 | 109 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 4839 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 19894 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2014 | 151 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2014 | 195 | 0.030 |
Why?
|
| Immunogenetic Phenomena | 1 | 2013 | 23 | 0.030 |
Why?
|
| Ligands | 2 | 2012 | 3281 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21675 | 0.030 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2013 | 33 | 0.030 |
Why?
|
| Arthralgia | 1 | 2018 | 456 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 1104 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 399 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 906 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 936 | 0.030 |
Why?
|
| Mass Screening | 1 | 2009 | 5251 | 0.030 |
Why?
|
| Exanthema | 1 | 2018 | 501 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 2865 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1917 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2012 | 48 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 667 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 504 | 0.030 |
Why?
|
| Acute Disease | 1 | 2003 | 7150 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 5892 | 0.030 |
Why?
|
| Liposomes | 1 | 2016 | 759 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 1117 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2018 | 8316 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 505 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 1422 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 502 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2177 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 526 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 733 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 4459 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 452 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2015 | 1536 | 0.020 |
Why?
|
| Colitis | 1 | 2018 | 1170 | 0.020 |
Why?
|
| Telomere | 1 | 2016 | 910 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2014 | 2256 | 0.020 |
Why?
|
| Cell Separation | 1 | 2015 | 1750 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2022 | 2984 | 0.020 |
Why?
|
| Anemia | 1 | 2019 | 1502 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 697 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 4463 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2016 | 1599 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1415 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 3504 | 0.020 |
Why?
|
| Autophagy | 1 | 2017 | 1296 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5755 | 0.020 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2008 | 14 | 0.020 |
Why?
|
| Cell Shape | 1 | 2010 | 375 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2012 | 853 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 765 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2014 | 1958 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2617 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 999 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 3524 | 0.020 |
Why?
|
| RNA | 1 | 2019 | 2748 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2008 | 75 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2015 | 2634 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 2008 | 349 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2015 | 1782 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 3794 | 0.020 |
Why?
|
| United States | 3 | 2021 | 69859 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4777 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 3912 | 0.020 |
Why?
|
| Headache | 1 | 2015 | 1224 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6750 | 0.020 |
Why?
|
| Registries | 1 | 2023 | 8090 | 0.020 |
Why?
|
| Genome, Human | 1 | 2021 | 4418 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5986 | 0.020 |
Why?
|
| Pneumonia | 1 | 2019 | 2133 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2012 | 1402 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9677 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1758 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2011 | 1369 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3772 | 0.020 |
Why?
|
| Cytokines | 3 | 2011 | 7324 | 0.020 |
Why?
|
| Peptidoglycan | 1 | 2008 | 246 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 1678 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 1952 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3701 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 53250 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2006 | 203 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 363 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2018 | 2063 | 0.020 |
Why?
|
| Rheumatoid Factor | 1 | 2006 | 188 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2015 | 2969 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 12066 | 0.020 |
Why?
|
| Greece | 1 | 2006 | 344 | 0.020 |
Why?
|
| Doxycycline | 1 | 2007 | 326 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 2503 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1482 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2008 | 572 | 0.020 |
Why?
|
| Environmental Health | 1 | 2007 | 278 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 213 | 0.020 |
Why?
|
| Spain | 1 | 2006 | 464 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 232 | 0.020 |
Why?
|
| France | 1 | 2006 | 517 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 3070 | 0.020 |
Why?
|
| DNA | 1 | 2019 | 7295 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2016 | 40964 | 0.020 |
Why?
|
| CpG Islands | 1 | 2008 | 1170 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2006 | 1095 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2010 | 3680 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1904 | 0.010 |
Why?
|
| Cell Migration Inhibition | 1 | 2003 | 96 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2005 | 645 | 0.010 |
Why?
|
| Chemokine CXCL9 | 1 | 2003 | 132 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2010 | 1537 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13980 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 2004 | 435 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8637 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10940 | 0.010 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 72 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 3338 | 0.010 |
Why?
|
| Interferon-gamma | 2 | 2004 | 3205 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2008 | 1172 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2003 | 357 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2014 | 2146 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2003 | 305 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2003 | 320 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 193 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6356 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2010 | 2963 | 0.010 |
Why?
|
| Amino Acids | 1 | 2007 | 1733 | 0.010 |
Why?
|
| Proteomics | 1 | 2014 | 3639 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12243 | 0.010 |
Why?
|
| Chromatin | 1 | 2012 | 2931 | 0.010 |
Why?
|
| International Cooperation | 1 | 2006 | 1419 | 0.010 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1999 | 134 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 2050 | 0.010 |
Why?
|
| Binding Sites | 1 | 2007 | 6111 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 3850 | 0.010 |
Why?
|
| Algorithms | 1 | 2018 | 13869 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 707 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 420 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 2131 | 0.010 |
Why?
|
| Inflammation | 1 | 2017 | 10629 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2005 | 1986 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 518 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 240 | 0.010 |
Why?
|
| Endothelium | 1 | 1999 | 777 | 0.010 |
Why?
|
| Child | 3 | 2016 | 77637 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 1159 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 12944 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2003 | 1743 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23327 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4568 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 1409 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 2927 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 2475 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 7479 | 0.010 |
Why?
|
| Infant | 2 | 2005 | 35122 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 2958 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 4974 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 7172 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 25609 | 0.000 |
Why?
|